Sekiya M

No ORCID on file · 3 papers in corpus · active 2024-2026

Study types

  • other 2

Condition tags

  • endometriosis 2
other 2026
Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial
F&S reports ·doi:10.1016/j.xfre.2025.12.008
other 2025
Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial
F&S reports ·doi:10.1016/j.xfre.2025.04.009

OBJECTIVE: To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis. DESIGN: A multicente…

2024
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
Journal for immunotherapy of cancer ·doi:10.1136/jitc-2024-009262

BackgroundImmunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to immun…